On January 9, the U.S. Supreme Court denied a Pfizer cert petition without comment. Pfizer had argued that a Pfizer patient assistance program to cover the high cost-sharing amounts owed by Medicare beneficiaries for treatment with one of Pfizer’s cardiovascular drugs would not violate the federal healthcare anti-kickback act because the Pfizer drug in question held patent protection.